Why Are Pretreatment Prostate-specific Antigen Levels And Biochemical Recurrence Poor Predictors Of Prostate Cancer Survival?
UroToday.com - In the online edition of Cancer, Dr. James Denham and colleagues evaluated the initial, pretreatment PSA (iPSA) level as a prognostic predictor of prostate cancer (CaP) survival. A cohort of 802 patients from Australia and New Zealand received radiotherapy (XRT) with either 0, 3, or 6 months of neoadjuvant androgen deprivation therapy (ADT). Trial endpoints were biochemical recurrence free survival (BRFS) and prostate cancer specific survival (PCSS).
Original post by Allergy News From Medical News Today
Related Articles
Role Of MRI In Targeting Prostate Cancer In Patients With Previous Negative Biopsies And Elevated Prostate-Specific Antigen Levels
In Certain Elderly Populations Regular Prostate-Specific Antigen Screening May Be Discontinued
Salvage Options For Biochemical Recurrence After Primary Therapy For Prostate Cancer
Rising PSA In Nonmetastatic Prostate Cancer
Predictors Of Patient Reported Outcomes And Cost Of Care In Younger Men With Newly Diagnosed Prostate Cancer
Role Of MRI In Targeting Prostate Cancer In Patients With Previous Negative Biopsies And Elevated Prostate-Specific Antigen Levels
In Certain Elderly Populations Regular Prostate-Specific Antigen Screening May Be Discontinued
Salvage Options For Biochemical Recurrence After Primary Therapy For Prostate Cancer
Rising PSA In Nonmetastatic Prostate Cancer
Predictors Of Patient Reported Outcomes And Cost Of Care In Younger Men With Newly Diagnosed Prostate Cancer